Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3018]

Modulating the DNA damage response: The role of cell cycle checkpoint inhibitors

Dr Shivaani Kummar - Stanford University, Stanford, USA

Modulating the DNA damage response: The role of cell cycle checkpoint inhibitors ( Dr Shivaani Kummar - Stanford University, Stanford, USA )

Comment on RESONATE2 and CLL115 trials

Dr Peter Hillmen - Leeds Teaching Hospitals NHS Trust, Leeds, UK

Comment on RESONATE2 and CLL115 trials ( Dr Peter Hillmen - Leeds Teaching Hospitals NHS Trust, Leeds, UK )

Clinical cases employing novel agents in Hodgkin lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Centre, New York, USA

Clinical cases employing novel agents in Hodgkin lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Centre, New York, USA )

Microenvironment of chronic lymphocytic leukaemia

Dr George Follows, Cambridge University Hospitals NHS Foundation Trust...

Microenvironment of chronic lymphocytic leukaemia ( Dr George Follows, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK )

Current trials in chronic lymphocytic leukaemia

Dr George Follows - Cambridge University Hospitals NHS Foundation Trust...

Current trials in chronic lymphocytic leukaemia ( Dr George Follows - Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK )

Chronic lymphocytic leukaemia: Transition to a new era

Prof Stephen Mulligan - Royal North Shore Hospital, Australia

Chronic lymphocytic leukaemia: Transition to a new era ( Prof Stephen Mulligan - Royal North Shore Hospital, Australia )

Ibrutinib as a frontline therapy in RESONATE2 trials for CLL

Prof Jan Burger, MD Anderson Cancer Center, Texas, USA

Ibrutinib as a frontline therapy in RESONATE2 trials for CLL ( Prof Jan Burger, MD Anderson Cancer Center, Texas, USA )

Multi-target S-DNA increases colorectal cancer screening among previously non...

Dr Barry Berger - Exact Sciences, Madison, USA

Multi-target S-DNA increases colorectal cancer screening among previously non-compliant patients ( Dr Barry Berger - Exact Sciences, Madison, USA )

p62: Metabolism and the tumour microenvironment

Prof Jorge Moscat - Sanford Burnahm Prebys Medical Discovery Institute, La...

p62: Metabolism and the tumour microenvironment ( Prof Jorge Moscat - Sanford Burnahm Prebys Medical Discovery Institute, La Jolla, USA )

Cancer cells plasticity and drug resistance

Dr Rafaella Sordella - Cold Harbor Spring Laboratory, New York, USA

Cancer cells plasticity and drug resistance ( Dr Rafaella Sordella - Cold Harbor Spring Laboratory, New York, USA )

Targeted therapy shows continued promise in patients whose tumours had NTRK...

Dr David Hong - University of Texas MD Anderson Cancer Center, Houston, USA

Targeted therapy shows continued promise in patients whose tumours had NTRK gene fusions ( Dr David Hong - University of Texas MD Anderson Cancer Center, Houston, USA )

Drugging “undruggable” transcription factor drivers in cancer

Dr John Bushweller - Unviersity of Virgina, Virginia, USA

Drugging “undruggable” transcription factor drivers in cancer ( Dr John Bushweller - Unviersity of Virgina, Virginia, USA )

More from ecancer